PSA Screening

Latest news

Tag

Low Baseline PSA Predicts Exceptional Long-Term Safety: A 20-Year Paradigm Shift in Prostate Cancer Screening

A 20-year cohort study shows that baseline PSA levels in men aged 45-70 are highly predictive of long-term prostate cancer risk, with PSA <1.0 ng/mL indicating a very low 20-year incidence of 3.3%, supporting extended screening intervals

Feb 9, 2026

Clinical Updates

Stockholm3 Versus PSA in Prostate Cancer Screening: A Synthesis of 9-year Outcomes, Repeat Screening, and Multiethnic Validation

This review synthesizes long-term outcomes and multiethnic data demonstrating that the Stockholm3 test significantly improves the detection of aggressive prostate cancer while reducing overdiagnosis and unnecessary procedures compared to tr

Jan 9, 2026

news

European Prostate Cancer Screening After 23 Years: Sustained Mortality Reduction and Improved Harm-Benefit Profile

The 23-year follow-up of the ERSPC confirms that PSA screening reduces prostate cancer mortality by 13%, with an improved harm-benefit ratio, supporting risk-based screening strategies to optimize outcomes.

Oct 31, 2025Sign in to read